Research programme: cardiosphere-derived stem cell therapeutics - Capricor Therapeutics

Drug Profile

Research programme: cardiosphere-derived stem cell therapeutics - Capricor Therapeutics

Alternative Names: CDC therapeutics - Capricor; CPI-002; CPI-004; CPI-005

Latest Information Update: 24 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Capricor
  • Developer Capricor Therapeutics; Cedars-Sinai Health System; Johns Hopkins University School of Medicine
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chronic heart failure; Myocardial infarction

Most Recent Events

  • 11 Nov 2017 Cardiosphere-derived stem cell therapeutics is still undergoing preclinical development for Chronic heart failure and Myocardial infarction in USA
  • 11 Nov 2017 Pharmacodynamics data from a preclinical trial in Myocardial infarction presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA/ASA-2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-heart-failure in USA (Intracoronary, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top